INGN-241. Introgen.
Introgen, under license from Corixa (formerly GenQuest), is developing INGN-241, a gene therapy based on the mda-7 gene in combination with the company's adenoviral delivery system, for the potential treatment of cancer. A phase I trial for the treatment of solid tumors was initiated at the end of November 2000.
Gopalkrishnan
Rahul
R
Columbia University, College of Physicians and Surgeons, Department of Pathology, Box 23 BB 1505, 630 West 168 Street, New York, NY 10032, USA. rg285@columbia.edu
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007378:Interleukins / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000821:virology; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*; D000099180:Interleukin-24
D007378:Interleukins; D000099180:Interleukin-24